Cytosorbents (NASDAQ:CTSO – Get Free Report) is set to issue its quarterly earnings data after the market closes on Thursday, November 7th. Analysts expect the company to announce earnings of ($0.06) per share for the quarter. Parties that are interested in registering for the company’s conference call can do so using this link.
Cytosorbents (NASDAQ:CTSO – Get Free Report) last issued its quarterly earnings results on Tuesday, August 13th. The medical research company reported ($0.08) EPS for the quarter, topping the consensus estimate of ($0.09) by $0.01. The company had revenue of $9.89 million during the quarter, compared to analyst estimates of $9.73 million. Cytosorbents had a negative net margin of 68.70% and a negative return on equity of 131.84%. During the same quarter in the previous year, the firm earned ($0.14) EPS. On average, analysts expect Cytosorbents to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.
Cytosorbents Price Performance
Shares of NASDAQ CTSO opened at $0.86 on Wednesday. Cytosorbents has a one year low of $0.70 and a one year high of $2.15. The company has a debt-to-equity ratio of 0.82, a quick ratio of 1.71 and a current ratio of 2.12. The firm has a fifty day moving average of $1.15 and a 200 day moving average of $1.01. The firm has a market cap of $46.93 million, a PE ratio of -1.68 and a beta of 0.56.
Analyst Ratings Changes
View Our Latest Stock Analysis on CTSO
Cytosorbents Company Profile
Cytosorbents Corporation engages in the research, development, and commercialization of medical devices with its blood purification technology platform incorporating a proprietary adsorbent and porous polymer technology in the United States, Germany, and internationally. Its flagship product is CytoSorb, an extracorporeal cytokine adsorber for adjunctive therapy in the treatment of sepsis, adjunctive therapy in other critical care applications, prevention, and treatment of perioperative complications, and maintaining or enhancing the quality of solid organs harvested from donors for organ transplant; and offers VetResQ, a device for adjunctive therapy in the treatment of sepsis, pancreatitis, and other critical illnesses in animals.
See Also
- Five stocks we like better than Cytosorbents
- The Risks of Owning Bonds
- Palantir Cracks $50, Is There Still Time to Get on Board?
- Low PE Growth Stocks: Unlocking Investment Opportunities
- Insider Buying Signals Upside for These 3 Stocks
- Election Stocks: How Elections Affect the Stock Market
- These 2 Big Players Are Set to Compete With Elon Musk’s Starlink
Receive News & Ratings for Cytosorbents Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cytosorbents and related companies with MarketBeat.com's FREE daily email newsletter.